Back

Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials in type 2 diabetes: a meta-analysis of individual patient data

27 August 2022 (15:15 - 15:55)
Organised by:
Congress Presentation Part of: Anti-diabetic pharmacotherapy in clinical practice Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mr Georg Wolff

Clinic Ibbenburen, Ibbenbüren (Germany)

5 More presentations in this session

Presentation thumbnail
The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice.
Doctor A. Shiraki (Saga, JP)
Abstract Slides
Presentation thumbnail
Empagliflozin rescues primary murine cardiac fibroblasts, but not cardiomyocytes, from hypoxia-reoxygenation injury through STAT3-mediated cascades.
Mrs P. Nikolaou (Athens, GR)
Abstract Slides
Presentation thumbnail
Anti-inflammatory potential of SGLT2 inhibitors: a systematic review and meta-analysis of preclinical studies in rodents
Doctor M. Sagris (Athens, GR)
Abstract Slides
Presentation thumbnail
Four-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus.
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides
Presentation thumbnail
Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease
Doctor M. Elmegaard (Copenhagen, DK) Doctor A. Falkentoft (Roskilde, DK)
Abstract Slides

Access the full session

Session thumbnail
Anti-diabetic pharmacotherapy in clinical practice

The Event

Event poster

ESC Congress 2022

27 August 2022 15:15 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources